Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Treatment
26 results:

  • 1. JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.
    Pennel KAF; Hatthakarnkul P; Wood CS; Lian GY; Al-Badran SSF; Quinn JA; Legrini A; Inthagard J; Alexander PG; van Wyk H; Kurniawan A; Hashmi U; Gillespie MA; Mills M; Ammar A; Hay J; Andersen D; Nixon C; Rebus S; Chang DK; Kelly C; Harkin A; Graham J; Church D; Tomlinson I; Saunders M; Iveson T; Lannagan TRM; Jackstadt R; Maka N; Horgan PG; Roxburgh CSD; Sansom OJ; McMillan DC; Steele CW; Jamieson NB; Park JH; Roseweir AK; Edwards J
    J Exp Clin Cancer Res; 2024 Mar; 43(1):64. PubMed ID: 38424636
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. SKAP1 Is a Novel Biomarker and Therapeutic Target for Gastric cancer: Evidence from Expression, Functional, and Bioinformatic Analyses.
    Zhu L; Yu Q; Li Y; Zhang M; Peng Z; Wang S; Quan Z; Gao D
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511629
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Hyperforin Suppresses Oncogenic Kinases and Induces Apoptosis in colorectal cancer Cells.
    Hsu LC; Kuo CY; Hsu FT; Chang HF; Ou JJ
    In Vivo; 2023; 37(1):182-189. PubMed ID: 36593022
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Downregulation of SLC9A8 Promotes Epithelial-Mesenchymal Transition and Metastasis in colorectal cancer Cells via the IL6-jak1/STAT3 Signaling Pathway.
    Liu W; Geng C; Li X; Li Y; Song S; Wang C
    Dig Dis Sci; 2023 May; 68(5):1873-1884. PubMed ID: 36583805
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Microsatellite Instability-High Endometrial cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles.
    Manning-Geist BL; Liu YL; Devereaux KA; Paula ADC; Zhou QC; Ma W; Selenica P; Ceyhan-Birsoy O; Moukarzel LA; Hoang T; Gordhandas S; Rubinstein MM; Friedman CF; Aghajanian C; Abu-Rustum NR; Stadler ZK; Reis-Filho JS; Iasonos A; Zamarin D; Ellenson LH; Lakhman Y; Mandelker DL; Weigelt B
    Clin Cancer Res; 2022 Oct; 28(19):4302-4311. PubMed ID: 35849120
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Laparoscopic liver resection for colorectal liver metastases: retrospective analysis of prognostic factors and oncological outcomes in a single-center cohort.
    Taillieu E; De Meyere C; Nuytens F; Vanneste G; Libbrecht L; Alaerts H; Parmentier I; Verslype C; D'Hondt M
    Langenbecks Arch Surg; 2022 Sep; 407(6):2399-2414. PubMed ID: 35499586
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. CJ14939, a Novel JAK Inhibitor, Increases Oxaliplatin-induced Cell Death Through JAK/STAT Pathway in colorectal cancer.
    Hong JK; Kim DY; Shin JS; Ryu YS; Moon JH; Koh DI; Lee S; Lee J; Lee WJ; Lee EY; Jung SA; Kim SC; Yu HN; Kim MJ; Hong SW; Park SS; Jung J; Kim SM; Kim EH; Jeong HR; Gong JH; Kim J; Kim TW; Jin DH
    Anticancer Res; 2022 Apr; 42(4):1813-1819. PubMed ID: 35346999
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Effects of Vitexin, a Natural Flavonoid Glycoside, on the Proliferation, Invasion, and Apoptosis of Human U251 Glioblastoma Cells.
    Huang J; Zhou Y; Zhong X; Su F; Xu L
    Oxid Med Cell Longev; 2022; 2022():3129155. PubMed ID: 35281458
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced colorectal cancer: A Case Series.
    Zhou C; Jiang T; Xiao Y; Wang Q; Zeng Z; Cai P; Zhao Y; Zhao Z; Wu D; Lin H; Sun C; Zhang R; Xiao W; Gao Y
    Front Immunol; 2021; 12():784336. PubMed ID: 34975873
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. MicroRNA 452 regulates IL20RA-mediated jak1/STAT3 pathway in inflammatory colitis and colorectal cancer.
    Lamichhane S; Mo JS; Sharma G; Choi TY; Chae SC
    Inflamm Res; 2021 Aug; 70(8):903-914. PubMed ID: 34283251
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab.
    Trilla-Fuertes L; Gámez-Pozo A; Maurel J; Garcia-Carbonero R; Capdevila J; G-Pastrián L; Mendiola M; Peña C; López-Vacas R; Cuatrecasas M; García-Alfonso P; Ramos-Ruiz R; Llorens C; Ghanem I; Conill C; Heredia-Soto V; Campos-Barros Á; Fresno Vara JÁ; Feliu J
    Sci Rep; 2021 Apr; 11(1):7402. PubMed ID: 33795829
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma.
    Grant RC; Denroche R; Jang GH; Nowak KM; Zhang A; Borgida A; Holter S; Topham JT; Wilson J; Dodd A; Jang R; Prince R; Karasinska JM; Schaeffer DF; Wang Y; Zogopoulos G; Berry S; Simeone D; Renouf DJ; Notta F; O'Kane G; Knox J; Fischer S; Gallinger S
    Gut; 2021 Oct; 70(10):1894-1903. PubMed ID: 32933947
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells.
    Wang Z; Li MY; Zhang ZH; Zuo HX; Wang JY; Xing Y; Ri M; Jin HL; Jin CH; Xu GH; Piao LX; Jiang CG; Ma J; Jin X
    Pharmacol Res; 2020 May; 155():104727. PubMed ID: 32113874
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer.
    Giordano G; Parcesepe P; D'Andrea MR; Coppola L; Di Raimo T; Remo A; Manfrin E; Fiorini C; Scarpa A; Amoreo CA; Conciatori F; Milella M; Caruso FP; Cerulo L; Porras A; Pancione M
    J Exp Clin Cancer Res; 2019 Jan; 38(1):28. PubMed ID: 30670049
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
    Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
    Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors.
    Al-Hader A; Al-Rohil RN; Han H; Von Hoff D
    World J Gastroenterol; 2017 Dec; 23(45):7945-7951. PubMed ID: 29259370
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of jak1 mutations and consensus molecular subtype 1.
    Sveen A; Johannessen B; Tengs T; Danielsen SA; Eilertsen IA; Lind GE; Berg KCG; Leithe E; Meza-Zepeda LA; Domingo E; Myklebost O; Kerr D; Tomlinson I; Nesbakken A; Skotheim RI; Lothe RA
    Genome Med; 2017 May; 9(1):46. PubMed ID: 28539123
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Prognostic and Predictive Biomarkers in colorectal cancer. From the Preclinical Setting to Clinical Practice.
    Maurel J; Postigo A
    Curr Cancer Drug Targets; 2015; 15(8):703-15. PubMed ID: 26452385
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer.
    Van Schaeybroeck S; Kalimutho M; Dunne PD; Carson R; Allen W; Jithesh PV; Redmond KL; Sasazuki T; Shirasawa S; Blayney J; Michieli P; Fenning C; Lenz HJ; Lawler M; Longley DB; Johnston PG
    Cell Rep; 2014 Jun; 7(6):1940-55. PubMed ID: 24931611
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. INCB018424 induces apoptotic cell death through the suppression of pjak1 in human colon cancer cells.
    An HJ; Choi EK; Kim JS; Hong SW; Moon JH; Shin JS; Ha SH; Kim KP; Hong YS; Lee JL; Choi EK; Lee JS; Jin DH; Kim TW
    Neoplasma; 2014; 61(1):56-62. PubMed ID: 24195509
    [TBL] [Abstract] [Full Text] [Related]  


    of 2.